Farxiga Cost in Nevada 2026: Cash Price, Insurance, Medicaid, and Compounded Options

Dapagliflozin, sold under the brand name Farxiga (AstraZeneca), is an SGLT2 inhibitor tablet taken once daily in 5 mg or 10 mg strength. It carries FDA-approved indications for type 2 diabetes, heart failure across the ejection fraction range, and chronic kidney disease. No FDA-approved generic dapagliflozin exists in the United States as of this writing, so cost in Nevada is shaped almost entirely by brand pricing, insurance tier placement, and manufacturer discount programs rather than by generic competition. What follows separates the facts that are stable and verifiable (FDA approval status, drug class, legal framework for compounding and telehealth) from the facts that change often and that this article cannot certify as current (a specific cash price, a specific Medicaid formulary status, a specific insurer copay, or a specific savings-card cap).

What does Farxiga actually cost in Nevada?

There is no single, stable number for "the Farxiga price in Nevada." Brand-name list price (wholesale acquisition cost) is set by AstraZeneca and applies nationally, but the price a given patient pays depends on the specific pharmacy, whether a discount card or manufacturer coupon is applied, and whether insurance covers the fill at all. Public price-comparison tools and pharmacy call-arounds commonly report brand dapagliflozin in the range of several hundred dollars for a 30-tablet, 10 mg supply, but this article does not have a verified, dated local price to cite with confidence, and quoting a single fixed figure would overstate certainty that does not exist. The most reliable approach for a Nevada patient is to call two or three pharmacies (a chain pharmacy, an independent, and a mail-order or telepharmacy option) and compare same-day quotes, since prices can differ meaningfully between them.

The current FDA-approved label for dapagliflozin documents the approved dosage forms, strengths, and indications, but it does not set or disclose price. Because no generic exists, ordinary generic substitution at the pharmacy counter is not available, which removes one of the usual mechanisms that lowers brand-drug prices over time.

Does Nevada Medicaid cover Farxiga?

Nevada Medicaid manages a Preferred Drug List (PDL) through the Division of Welfare and Supportive Services, and dapagliflozin has been reported in the past as sitting off that formulary without a routine approval pathway for most recipients. That status is a formulary fact, not a clinical or regulatory fact, and formularies are revised periodically. This article does not have a dated, verifiable citation confirming Farxiga's current PDL status, so the accurate statement for a reader is: verify directly with Nevada Medicaid or your managed care plan before assuming coverage or non-coverage, and ask your prescriber about a prior-authorization or medical-necessity request if the drug is not listed.

If dapagliflozin is not accessible through Medicaid, alternatives exist for each indication but do not replicate its exact mechanism. For type 2 diabetes, other Medicaid-preferred agents such as metformin or sulfonylureas may be listed. For heart failure with reduced ejection fraction, other guideline-recommended drug classes (such as beta-blockers or ARNI therapy) may be covered. Whether an SGLT2 inhibitor specifically is clinically substitutable depends on the patient's full history and should be decided with the prescribing clinician, not inferred from a formulary alone.

How does commercial insurance in Nevada typically handle Farxiga?

Most commercial plans that operate in Nevada include SGLT2 inhibitors like Farxiga on formulary, usually as a preferred or non-preferred brand tier, but exact tier placement, copay amount, and prior-authorization criteria vary by carrier and by plan year and are not something this article can state precisely for any individual plan. Nevada Health Link, the state's ACA marketplace, allows members to view a plan's specific formulary before enrolling, which is the most reliable way to check tier placement for a given plan year.

Prior authorization is common for the heart failure and CKD indications specifically. Insurers frequently ask for documentation such as an HbA1c value for the diabetes indication or an ejection fraction measurement for the heart failure indication before approving coverage. The 2022 AHA/ACC/HFSA heart failure guideline update classifies SGLT2 inhibitors as a strongly recommended therapy for symptomatic heart failure with reduced ejection fraction, which is useful supporting evidence for a prior-authorization appeal, though the exact grading language should be checked against the current published guideline rather than restated from memory here.

AstraZeneca's savings card and patient assistance program

AstraZeneca operates a commercial-insurance savings card for Farxiga and a separate income-based assistance program (branded AZ&Me in past program years) for patients who are uninsured or underinsured. In general terms:

• The commercial savings card is available only to patients with private insurance; Medicare, Medicaid, and CHIP enrollees are typically excluded from manufacturer copay cards under federal anti-kickback rules that apply broadly across the industry.
• Income-based assistance programs for uninsured patients typically use a federal poverty level threshold that is updated periodically.
• Both programs require the prescription to be for an FDA-approved indication and are subject to per-fill limits and program terms that change.

Because savings-card dollar caps, per-fill limits, and income thresholds are the kind of detail that manufacturers update without much notice, this article intentionally does not restate a specific dollar cap or income cutoff as current fact. Confirm the live terms directly on AstraZeneca's official Farxiga patient support page before relying on a specific number.

Is compounded dapagliflozin legal in Nevada?

Yes, with conditions. Section 503A of the Federal Food, Drug, and Cosmetic Act allows a licensed pharmacy to compound a medication for an individual patient with a valid prescription, generally when a commercially available product does not meet a specific documented patient need (for example, a different strength, an excipient the patient cannot tolerate, or a different dosage form). A 503A pharmacy operating in Nevada must be licensed by the Nevada State Board of Pharmacy, and an out-of-state 503A pharmacy shipping into Nevada must hold a Nevada non-resident pharmacy permit.

Two things matter clinically here. First, a compounded drug is not FDA-approved, which means the agency has not verified its potency, purity, or bioequivalence to the branded tablet the way it does for an approved generic. Second, compounded dapagliflozin is not covered by commercial insurance or Medicaid, so any price advantage has to be weighed against paying entirely out of pocket and against the absence of FDA bioequivalence review. Anyone considering this route should ask the pharmacy directly about its accreditation status (for example, PCAB accreditation) and should discuss the clinical rationale with the prescribing clinician rather than choosing a compounded product for price alone.

Can Farxiga be prescribed by telehealth in Nevada?

Yes. Nevada's telehealth statute, NRS Chapter 629, permits a licensed Nevada prescriber, or an out-of-state prescriber holding a Nevada telemedicine registration, to conduct a synchronous evaluation and issue a prescription for a non-controlled medication such as dapagliflozin. Dapagliflozin is not a controlled substance, so DEA special telehealth registration requirements that apply to controlled-substance prescribing do not apply here.

A responsible telehealth visit for this drug should still include a review of relevant labs, particularly eGFR, since dapagliflozin's labeled use depends on kidney function. The diabetes indication is not recommended for initiation below an eGFR of 45 mL/min/1.73 m2 per the FDA label, while the CKD indication extends to a lower eGFR threshold; the exact cutoffs and any label updates should be confirmed against the current label rather than assumed from a general description.

What the CKD indication changes for coverage

The FDA expanded dapagliflozin's approval to include chronic kidney disease, with or without type 2 diabetes, based on a large kidney-outcomes trial (DAPA-CKD). Kidney disease guideline bodies, including KDIGO, have given SGLT2 inhibitors a strong recommendation for appropriate patients with type 2 diabetes and CKD above a specified eGFR floor. This article does not carry a verified citation for the exact guideline wording or the precise eGFR cutoff used in the current KDIGO recommendation, so a clinician filing a prior-authorization appeal citing a "Grade 1A" or similarly worded recommendation should pull the exact language directly from the current published guideline rather than from a secondary restatement.

Practically, whether a Nevada commercial plan has updated its prior-authorization criteria to reflect the CKD indication varies by insurer and by plan year. Patients with an eGFR in the range where the CKD indication applies but the diabetes indication does not should make sure the prescription and prior-authorization paperwork document the CKD indication specifically, since insurers process the two indications differently.

How does Farxiga's price compare with other SGLT2 inhibitors?

Empagliflozin (Jardiance) and canagliflozin (Invokana) are brand-name SGLT2 inhibitors with similar mechanisms and, as of this writing, no FDA-approved generics of their own, so price competition within the class has been limited overall. The 2022 AHA/ACC/HFSA heart failure guideline recommends the SGLT2 inhibitor class for heart failure with reduced ejection fraction rather than preferring one specific agent, which means a formulary-driven switch (for example, to whichever agent a given commercial plan places on a lower tier) is a reasonable cost-saving conversation to have with a prescriber, provided the substitute agent's approved indications match the patient's clinical need. Ertugliflozin (Steglatro) has a narrower approved indication set, limited to type 2 diabetes, and is not an appropriate substitute for a patient being treated for heart failure or CKD.

What is established, what is plausible, and what is not established

Established: dapagliflozin is FDA-approved for type 2 diabetes, heart failure, and chronic kidney disease; no FDA-approved generic exists in the U.S. as of this writing; compounding by a properly licensed 503A pharmacy is legal under federal and Nevada law; telehealth prescribing of this non-controlled drug is legal in Nevada under NRS 629.

Plausible but not verified in this article with a dated local source: any specific dollar figure for Nevada cash price, any specific commercial insurer's tier placement or copay range, the current Nevada Medicaid PDL status for dapagliflozin, and the current dollar cap or eligibility threshold for AstraZeneca's savings or assistance programs.

Not established here: that compounded dapagliflozin from any specific Nevada pharmacy is bioequivalent to the branded tablet, or that any single insurance or assistance pathway will produce a specific dollar outcome for an individual patient. Coverage and pricing decisions depend on plan-year details that this article cannot certify as current.

Verification checklist: what is stable versus what you must re-check before relying on it

Use this before making a coverage or cost decision. Items in the first group rarely change and can be trusted as background. Items in the second group are date-sensitive and should be confirmed the same week you act on them.

Stable, federal or clinical facts (verify once, unlikely to change often):

• FDA-approved indications for dapagliflozin (type 2 diabetes, heart failure, CKD), confirm against the current FDA label
• Whether a generic dapagliflozin has been approved in the U.S., check the FDA's Orange Book if this matters to your decision
• Legal framework for 503A compounding, confirmed by federal statute and FDA guidance
• Legal framework for telehealth prescribing in Nevada, confirmed by NRS Chapter 629
• eGFR-based contraindications and dosing thresholds described on the current label

Date-sensitive facts you must re-verify before acting (these change without notice):

• Your specific pharmacy's current cash price for the strength and quantity you need
• Whether Nevada Medicaid or your specific Medicaid managed care plan currently lists dapagliflozin on its preferred drug list, and what its prior-authorization process requires
• Your specific commercial plan's current formulary tier, copay, and prior-authorization criteria for this plan year
• The current terms of any AstraZeneca savings card or patient assistance program, including eligibility, dollar cap, and per-fill limits
• Whether a specific 503A pharmacy is currently licensed in Nevada (or holds a valid non-resident permit) and what quality accreditation it carries
• Whether your telehealth provider is currently licensed in Nevada or holds an active Nevada telemedicine registration

If a number you were given (a price, a copay, a savings-card cap, a coverage decision) does not match what you confirm through one of the stable sources above or a direct call to the payer or pharmacy, treat the confirmed, dated answer as correct and the older number as outdated.

Practical steps to reduce cost

Work more than one lever at once rather than relying on a single program.

Check your plan's formulary directly, through your insurer's member portal or Nevada Health Link if you have a marketplace plan, and note the tier and any step-therapy requirement before assuming coverage. If your commercial plan covers the drug, ask the pharmacist about applying a manufacturer savings card at the counter; most require no separate pre-registration. If you are on Nevada Medicaid, ask your prescriber to file a prior-authorization or medical-necessity request rather than assuming automatic denial. If you are uninsured and income-eligible, look into AstraZeneca's patient assistance program directly rather than a specific dollar figure quoted secondhand. If none of these produce affordable access and your prescriber agrees there is a documented clinical reason, ask about a licensed Nevada 503A compounding pharmacy, understanding that insurance will not cover it and that bioequivalence to the branded product has not been FDA-verified. Avoid unlicensed international or online sellers; authenticity and dosing cannot be confirmed for those products.